Scholar Rock Aims for 2026 Apitegromab Resubmission After FDA Facility Review
Event summary
- Scholar Rock plans to resubmit its apitegromab BLA in 2026 following FDA reinspection of Catalent Indiana facility.
- Secured $550M debt facility from Blue Owl Capital for commercialization and pipeline advancement.
- Phase 2 FORGE trial for FSHD expected to initiate mid-2026; SRK-439 Phase 1 data anticipated in H2 2026.
- Reported $377.9M net loss for FY 2025, up from $246.3M in 2024.
The big picture
Scholar Rock's focus on myostatin biology positions it in the competitive neuromuscular disease space, where regulatory approvals and commercial execution are critical. The $550M debt facility provides runway for apitegromab launch and pipeline expansion, but success hinges on navigating FDA hurdles and demonstrating clinical efficacy across multiple indications.
What we're watching
- Regulatory Timing
- Whether FDA reinspection of Catalent Indiana will proceed smoothly and enable timely BLA resubmission.
- Commercial Readiness
- The pace at which Scholar Rock can scale manufacturing and commercial operations for apitegromab launch.
- Pipeline Progress
- How Phase 2 FORGE trial initiation and SRK-439 data will impact long-term growth prospects.
Our editorial coverage:
Related topics